Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Shenlingcao Oral Liquid for Patients With Stage II or IIIA Non-small Cell Lung Cancer Receiving Radical Resection: A Pragmatic, Multicenter Randomized Controlled Trial

NCT03712969 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT03712969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03712969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Shenlingcao Oral Liquid for Patients With Stage II or IIIA Non-small Cell Lung Cancer Receiving Radical Resection: A Pragmatic, Multicenter Randomized Controlled Trial
Lead sponsor
West China Hospital
Phase
Phase 4
Overall status
Completed
Start date
November 5, 2018
Completion date
May 4, 2023
Enrollment
527 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, chemotherapy, adjuvant